BAP1 and nonpapillary renal cell carcinoma: BAP1 mutations are present in 5–15% of ccRCC cases [16,33,45,46], and have been shown to be associated with metastatic disease at diagnosis, high Fuhrman grade, and presence of necrosis (the last two factors being clinical predictors of disease recurrence in localized disease) [47,48].